The multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency LEIDEN, Netherlands, Feb. 21, 2023 /PRNewswire/

Related Keywords

Japan , United States , Netherlands , United Kingdom , London , City Of , Amsterdam , Noord Holland , America , American , Manish Butte , Dennis Riedl , Ethan Metelenis , Heather Robertson , Michael Levitan , Dan Caley , Anurag Relan , E Richard Stiehm , Linkedin , Vp Investor Relations Corporate Communications , Drug Administration , Regulatory Agency , Nasdaq , Exchange Commission , American Society Of Hematology , Prnewswire Pharming Groupnv , European Medicines Agency , Department Of Pediatrics , Pharming Group , Lifespring Life Sciences Communication , Committee For Medicinal Products Human Use , Investor Relations Corporate Communications , Stiehm Endowed Chair , Division Chief , American Society , United Kingdom Medicines , Pediatric Investigation Plan , Chief Medical Officer , New Drug Application , Prescription Drug User Fee Act , Marketing Authorisation Application , Medicinal Products , Human Use , Activated Phosphoinositide , North America , Middle East , Annual Report , Allergy Clin , Rev Allergy , Investor Relations , Corporate Communications , Spring Life Sciences Communication , Pharming , Group , Nnounces , First , Patient , Unrolled , Pediatric , Linical , Trial , Eniolisib ,